SCHEMBL19713730

SCHEMBL19713730

CC(NC(=O)c1cc(Cl)cnc1Oc1cccc(F)c1)c1ccc(C(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 20/20 1.00
PTGER2 P43116 6/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31049762 1.00 PTGER4 (1.00) PTGER4PTGER2
SCHEMBL120617 1.00 PTGER4 (1.00) PTGER4PTGER2
SCHEMBL29373541 1.00 PTGER4 (1.00) PTGER4PTGER2
SCHEMBL5357769 0.92 PTGER4 (0.85) PTGER4PTGER2
SCHEMBL4448664 0.92 PTGER4 (0.84) PTGER4PTGER2
SCHEMBL691838 0.92 PTGER4 (1.00) PTGER4PTGER2
SCHEMBL19713765 0.92 PTGER4 (1.00) PTGER4PTGER2
SCHEMBL19713723 0.92 PTGER4 (0.85) PTGER4PTGER2
SCHEMBL1284715 0.92 PTGER4 (0.85) PTGER4PTGER2
SCHEMBL691746 0.90 PTGER4 (0.88) PTGER4PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697317-A Use of EP4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia 株式会社AskAt 2023-02-03 CN claimed
CN-108289960-B Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer 株式会社AskAt 2021-07-09 CN claimed
CN-117940166-A SOS1 inhibitors and RAS inhibitors for the treatment of pain 塞文莱斯治疗有限公司 2024-04-26 CN disclosed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN disclosed
CN-117858875-A Hydroxy-and (halo) alkoxy-substituted tetrahydrofurans as sodium channel modulators 沃泰克斯药物股份有限公司 2024-04-09 CN disclosed
CN-117813302-A Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators 沃泰克斯药物股份有限公司 2024-04-02 CN disclosed
CN-117794920-A N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators 沃泰克斯药物股份有限公司 2024-03-29 CN disclosed
CN-117794918-A Substituted tetrahydrofuran analogues as sodium channel modulators 沃泰克斯药物股份有限公司 2024-03-29 CN disclosed
CN-117794919-A N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamide analogues as sodium channel modulators 沃泰克斯药物股份有限公司 2024-03-29 CN disclosed
CN-117616022-A Crystalline forms 拉夸里亚创药株式会社 2024-02-27 CN disclosed
CN-111868037-B Fused cyclic urea derivatives as CRHR2 antagonists 拉夸里亚创药株式会社 2023-10-13 CN disclosed
CN-101616896-A Tricyclic compounds and as the purposes of glucocorticoid receptor modulator PFIZER PROD INC 2009-12-30 CN disclosed
CN-101595102-A Diaryl ether urea compounds PFIZER PROD INC (US) 2009-12-02 CN disclosed
CN-101356169-A Pyrazine derivatives PFIZER LTD (GB) 2009-01-28 CN disclosed
CN-101321738-A Spirocyclic derivatives PFIZER LTD (GB) 2008-12-10 CN disclosed
CN-101233139-A Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as ORL1-receptor antagonists PFIZER (US) 2008-07-30 CN disclosed
CN-101198606-A Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists PFIZER JAPAN INC (US) 2008-06-11 CN disclosed
CN-101160285-A Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists PFIZER (US) 2008-04-09 CN disclosed
CN-101065355-A N- [ (3s)- pyrrolidin-3-yl]- benzamide derivatives as monoamine re-uptake inhibitors PFIZER (US) 2007-10-31 CN disclosed
CN-1989107-A Pyridine derivatives PFIZER (US) 2007-06-27 CN disclosed